Details for Patent: 9,907,834

Which drugs does patent 9,907,834 protect, and when does it expire?

Patent 9,907,834 protects VOXZOGO and is included in one NDA.

This patent has twenty-seven patent family members in sixteen countries.

Summary for Patent: 9,907,834

Title:	Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Abstract:	The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
Inventor(s):	Bullens; Sherry (Novato, CA), Bunting; Stuart (Novato, CA), Chou; Tianwei (Novato, CA), Okhamafe; Augustus O. (Concord, CA), Price; Christopher P. (Aachen, DE), Wendt; Daniel J. (Novato, CA), Yap; Clarence (Novato, CA)
Assignee:	BioMarin Pharmaceutical Inc. (Novato, CA)
Application Number:	15/225,355
Patent Claim Types: see list of patent claims	Formulation;

Drugs Protected by US Patent 9,907,834

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-001	Nov 19, 2021		RX	Yes	Yes			Y
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-002	Nov 19, 2021		RX	Yes	Yes			Y
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-003	Nov 19, 2021		RX	Yes	Yes			Y

International Family Members for US Patent 9,907,834

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	105563
Australia	2016298425
Australia	2023200669
Brazil	112018001761